, that's correct. >> avantor, fantastic.hose who aren't familiar with avantor which came public about a year or so ago, am i correct on that? >> yeah. we went public in may of last year, and it's been a pretty reexciting ride since then. >> i'm sure it has been, and you're trading ahead of where you were then. not all ipos can say that obviously. for those who don't know the company, what do you do in the supply chain what do you supply that makes your company so important to the therapeutics and the vaccines that we're going to benefit from >> yeah, tyler, thanks for giving us the opportunity to highlight what we do we're really proud of the role we're playing in this pandemic we'll be providing mission critical products all along the pipeline to support testing as well as vaccine development and therapy development, and then ultimately we'll be providing ingredients that are used in the production of these -- of these vaccines. >> so give me an example without going too technical on a product that is critical to either the

when you look at the top 20 drugs -- avantor became public in may of last year. since the ipo, the stock is 96%. can it keep climbing let's take a closer look with the president and ceo of avantor. mr. doublefield, welcome to "mad money. >> thanks for having me, nice to be with you again. >> you have been at the heart of all of these, why are these vaccines so different cuicult t? we need a billion. what can we do to speed up the process and typically the therapeutic which is really difficult to make. can you walk us through because you are key to everything? >> i think you got the story right, jim we are excited of the role that we play here and bringing the end to the pandemic. we are helping with the development of technologies that we are all familiar with things like mrna, there is never been any approved therapy, they're using that technology. we are on the cutting edge of science here and the value of science have been on display these technologies have been incubated in the lab for quite some time but never been scaled to the types o f numbers and doses t

avantor, key to make vaccines and calvin mcdonald now at lulu with fabulous numbers. i love lulu. great and now, carl, i guess it's the next show i enjoyed the show >> it's always hard to say good-bye, jim, but we'll see you tonight, "mad money" at 6:00 p.m. of course with jim cramer right here on cnbc good tuesday morning, everybody. welcome to "squawk on the stree street". i'm carl quintanilla with david faber and morgan brennan we were up 208 or so at the early high but currently up 66 watching the fda briefing docs on dough mmoderna. our road map moderna on deck it's called highly effective, critical step toward emergency approval potentially this week >>> warren buffett's call for action, urging congress to extend aid to small businesses as d.c. debates new stimulus proposals. >>> apple shares, they are up and up nicely actually, almost 4% the company reportedly aiming for a 30% jump in iphone production for the first half of 2021 >>> first up here the rollout of the pfizer vaccine conditions. brian sullivan is on the road with morrison dixon as the pharma distributor distrib